Sara Lodi

Biography

Publications

• Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data.

  Lodi S, Yan S, Bovell-Ammon B, Christine PJ, Hsu HE, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Addiction 2025 Mar 19

  PMID: 40104887

• Time to direct-acting antiviral initiation and liver-related events in people with HIV and hepatitis C virus.

  Chalouni M, Van Santen DK, Berenguer J, Jarrin I, Miro JM, Klein MB, Young J, Torgersen J, Rentsch CT, Gill MJ, Epstein RL, Linas B, Zangerle R, Surial B, Rauch A, Touloumi G, Papadopoulos A, Wittkop L, Van Der Valk M, Boyd A, Monforte AD, Puoti M, Logan RW, Rein SM, Hernán MA, Lodi S. AIDS 2025 Jul 01

  PMID: 39970192

• Racial and Ethnic Disparities in Hepatitis C Care in Reproductive-Aged Women With Opioid Use Disorder.

  Biondi BE, Munroe S, Lavarin C, Curtis MR, Buzzee B, Lodi S, Epstein RL. Clin Infect Dis 2024 12 17

  PMID: 39356149

• The Impact of COVID-19 on Substance Use and Related Consequences Among Patients in Office-based Opioid Use Disorder Treatment.

  Weinstein ZM, Magane KM, Lodi S, Ventura AS, Bazzi AR, Blodgett J, Fielman S, Davoust M, Shea MG, Chen CA, Cheng A, Theisen J, Blakemore S, Saitz R. J Addict Med 2025 Jan-Feb 01

  PMID: 39101572

• Socioeconomic Status and CD4 Count Among People with HIV Who Inject Drugs in St. Petersburg, Russia.

  Idrisov B, Van Draanen J, Lodi S, Lunze K, Kimmel SD, Quinn EK, Truong V, Blokhina E, Gnatienko N, Krupitsky E, Samet JH, Williams EC. AIDS Behav 2024

  PMID: 38658481